MRNA:NSD-Moderna Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 40.43

Change

+0.16 (+0.40)%

Market Cap

USD 16.10B

Volume

4.23M

Analyst Target

USD 89.73
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+2.47 (+0.61%)

USD 120.60B
REGN Regeneron Pharmaceuticals Inc

+2.21 (+0.31%)

USD 84.94B
ARGX argenx NV ADR

+2.05 (+0.33%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

-0.75 (-0.31%)

USD 31.66B
BGNE BeiGene Ltd

+3.06 (+1.68%)

USD 20.24B
UTHR United Therapeutics Corporatio..

+3.23 (+0.90%)

USD 16.18B
RPRX Royalty Pharma Plc

+0.17 (+0.67%)

USD 15.27B
SMMT Summit Therapeutics PLC

+0.28 (+1.47%)

USD 13.67B
INCY Incyte Corporation

-0.35 (-0.50%)

USD 13.52B
INSM Insmed Inc

+0.14 (+0.20%)

USD 13.20B

ETFs Containing MRNA

MRN3:LSE Leverage Shares 3x Long M.. 300.47 % 0.00 %

N/A

USD 0.65M
MSGR 6.26 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 5.70 % 0.00 %

N/A

N/A
HVAX:CA 4.95 % 0.00 %

N/A

N/A
BTEC:SW iShares Nasdaq US Biotech.. 4.67 % 0.00 %

N/A

N/A
XNNV:XETRA Xtrackers MSCI Innovation.. 3.03 % 0.00 %

N/A

N/A
XNNS:LSE Xtrackers MSCI Innovation.. 3.01 % 0.00 %

N/A

N/A
XNNV:LSE Xtrackers MSCI Innovation.. 3.01 % 0.00 %

N/A

N/A
ASRP:XETRA BNP Paribas Easy ECPI Glo.. 2.69 % 0.00 %

N/A

N/A
FCTR First Trust Lunt U.S. Fac.. 1.68 % 0.00 %

+0.07 (+0.21%)

N/A
TAEQ 1.46 % 0.00 %

N/A

N/A
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

N/A

USD 3.44B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

+0.58 (+0.21%)

USD 0.08B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

+0.76 (+0.21%)

N/A
FLAG 0.00 % 1.52 %

N/A

N/A
BTEC 0.00 % 0.42 %

N/A

N/A
LS:CA 0.00 % 2.21 %

N/A

N/A
HWF:CA 0.00 % 0.00 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
RYH 0.00 % 0.40 %

N/A

N/A
XT iShares Exponential Techn.. 0.00 % 0.47 %

+0.06 (+0.21%)

N/A
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

+0.10 (+0.21%)

USD 0.04B
MRNS:LSE -299.96 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -59.35% 28% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.35% 28% F 13% F
Trailing 12 Months  
Capital Gain -59.07% 29% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.07% 29% F 14% F
Trailing 5 Years  
Capital Gain 107.12% 89% A- 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 107.12% 89% A- 86% B+
Average Annual (5 Year Horizon)  
Capital Gain 76.37% 82% B 91% A-
Dividend Return 76.37% 82% B 91% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 194.39% 25% F 12% F
Risk Adjusted Return 39.29% 89% A- 70% C-
Market Capitalization 16.10B 99% N/A 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector